+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Can Oxidation-Reduction Potential of Cerebrospinal Fluid Be a Monitoring Biomarker in Amyotrophic Lateral Sclerosis?



Can Oxidation-Reduction Potential of Cerebrospinal Fluid Be a Monitoring Biomarker in Amyotrophic Lateral Sclerosis?



Antioxidants and Redox Signaling 28(17): 1570-1575



The monitoring of progression in amyotrophic lateral sclerosis (ALS) relies on clinical outcome measures that take months to interpret, such as revised ALS functional rating scale (ALSFRS-R) score, with no approved biomarkers. A number of clinical studies have documented the involvement of oxidative stress in ALS pathology. Pertinent to this, we propose to evaluate oxidation-reduction potential (ORP) of cerebrospinal fluid (CSF) as a potential indicator of ALS progression. The case-control study included 24 patients with neurological non-neurodegenerative disorders (controls) and 82 ALS patients with different degrees of disease (ALSFRS-R score: 21-47). ORP was significantly higher in ALS patients than controls. It was not dependent on age or gender. A strong negative correlation was found between ORP and ALSFRS-R score for all patients and patients with spinal onset. In other words, ORP increased with ALS progression. No correlation was found for the subset of patients with bulbar onset, most likely because of the physical distance between neurodegenerative loci and the site of CSF collection. These results lead to the hypothesis that ORP of CSF has a potential as monitoring biomarker in ALS, particularly in the cohort of patients with spinal onset. Antioxid. Redox Signal. 28, 1570-1575.

(PDF emailed within 0-6 h: $19.90)

Accession: 059467128

Download citation: RISBibTeXText

PMID: 29113448

DOI: 10.1089/ars.2017.7433


Related references

Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. Molecular Neurobiology 2019, 2019

Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis 12(2): 144-147, 2011

Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis?. Biomarkers 19(7): 571-577, 2015

Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. Journal of Neurology 254(5): 575-580, 2007

Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dementia and Geriatric Cognitive Disorders 44(3-4): 144-152, 2017

Reduction in glucose concentration in the brain of mice inoculated with cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Arquivos de Neuro-Psiquiatria 48(4): 473-477, 1990

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Medicine 18(4): 551-560, 2016

The cerebrospinal fluid values of advanced oxidation protein products and total thiol content in patients with amyotrophic lateral sclerosis. Clinical Neurology and Neurosurgery 163: 33-38, 2017

Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment. Journal of Neuroinflammation 13(1): 131, 2017

Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neuroscience Letters 260(3): 204-206, Feb 5, 1999

Cerebrospinal fluid proteins in the course of amyotrophic lateral sclerosis. Revue Neurologique 125(5): 393-400, 1971

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. European Journal of Neurology 6(5): 597-600, Sept, 1999

Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neuroscience Letters 416(3): 257-260, 2007

Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. Journal of Neurology 231(2): 75-78, 1984

Cerebrospinal fluid cytotoxicity in lateral amyotrophic sclerosis. Neurologia 25(6): 364-373, 2011